



## Theravance to Webcast 2011 Annual Meeting of Stockholders on April 27, 2011

SOUTH SAN FRANCISCO, CA/April 20, 2011 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2011 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Wednesday, April 27, 2011.

An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the audio feed live via the internet may do so by visiting the company's web site at [www.theravance.com](http://www.theravance.com). To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the 2011 Annual Meeting of Stockholders will be available on the company's web site for 30 days through May 27, 2011. A telephone replay will also be available through 11:59 p.m. Eastern Daylight Time on May 4, 2011 by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering confirmation code 54413580.

### About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: the RELOVAIR™ program, the LAMA/LABA ('719/vilanterol (VI)) program and the Bifunctional Muscarinic Antagonist-Beta<sub>2</sub> Agonist (MABA) program, each with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist (PμMA) program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at [www.theravance.com](http://www.theravance.com).

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

RELOVAIR™ is a trademark of GlaxoSmithKline group of companies.

### Contact Information:

Michael W. Aguiar  
Senior Vice President and Chief Financial Officer  
650-808-4100  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)

# # #